What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy”In the company’s words, NCT06566261 on ClinicalTrials.gov
- Tested for
- Progressive Multiple Sclerosis
- Main trialPhase 1
- “This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.”In the company’s words, NCT06566261 on ClinicalTrials.gov
Other drugs for Progressive Multiple Sclerosis
- TolebrutinibSanofi · Phase 3
- OrelabrutinibBeijing InnoCare Pharma Tech Co., Ltd. · Phase 3
- RemibrutinibNovartis · Phase 3
- FenebrutinibRoche · Phase 3
- KYV-101Kyverna Therapeutics · Phase 2
- SUN-627Sundance Biosciences, Inc. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Feb 2026 | ABA-101 in Participants With Progressive Multiple Sclerosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026